

## United States Patent and Trademark Office

ENTTED STATES DEPARTMENT OF COMMERCE Guited States Patent and Trademark, Office Address: COMMISSIONER FOR PATENTS P.O. Bect 1450 Alexandria, Virginia 22313-1450 worse.uspfu.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/869,251	06/26/2001	Michael F. Novits	IR 3492NP-PC	2269
75	590 10/22/2003		EXAMINER	
Royal E Brigh		MOORE, MARGARET G		
Atofina Chemicals Inc 26th Floor			ART UNIT	PAPER NUMBER
2000 Market St	reet	1732		
Philadelphia, PA 19103-3222			DATE MAILED: 10/22/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
4 2 -	09/869,251	NOVITS ET AL.				
* Advisory Action	Examiner	Art Unit				
	Margaret G. Moore	1712				
The MAILING DATE of this communication appe		L				
THE REPLY FILED 19 September 2003 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3_months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).						
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE:  3. Applicant's reply has overcome the following rejection(s):						
Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: of reasons noted in the attached paper.						
The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7.⊠ For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.						
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: 26 and 27.	Claim(s) allowed: 26 and 27.					
Claim(s) objected to: <u>12 and 21-25</u> .						
Claim(s) rejected: <u>1, 3-5, 13-16, 18-20</u> .	Claim(s) rejected: <u>1, 3-5, 13-16, 18-20</u> .					
Claim(s) withdrawn from consideration:						
The proposed drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.						
Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)						
10. Other:  Margaret © Moore  Primary Examiner						
S. Patent and Trademark Office		Ayt Unit: 1712				

Application/Control Number: 09/869,251

Art Unit: 1712

## ATTACHMENT:

Applicants' remarks are not sufficient to render the instant claims unobvious over the teachings of Aoshima et al. Regarding applicants' comments about compression set, the Examiner first notes that page 2 of the specification (which applicants refer to as an example of the phrase "low compression set") indicates that low compression set is a property known to be associated with polymers that crosslink with organic peroxides. This would indicate then that low compression set would be associated with the composition in Aoshima et al., which crosslinks by means of an organic peroxide. Thus asserting that the instant composition has low compression set does not lend it patentability over the teachings of Aoshima et al., which according to applicants' specification, would also be expected to have low compression set. On the other hand, the Examiner notes that a prima facie case of obviousness (for a composition) does not require the solution of the same problem or recognition of the same advantages as the applicants invention.

Applicants' comment that some of the optional coagents in Aoshima et al. produce poor surface tackiness is not supported by the prior art since a main concern of Aoshima et al. is surface tackiness (see the abstract).

Finally, the fact that the bismaleimide coagent is not required in Aoshima but essential to the claimed invention does not mean that the prior art fails to render obvious a composition containing such a bismaleimide coagent.

For these reasons, applicants have failed to establish that the claimed composition is unobvious over the prior art.